We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

111 hedge funds and large institutions have $885M invested in Crinetics Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 46 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

51,340% more call options, than puts

Call options by funds: $2.57M | Put options by funds: $5K

48% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 31

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

1.1% less ownership

Funds ownership: 95.75% → 94.65% (-1.1%)

4% less funds holding

Funds holding: 116 → 111 (-5)

11% less capital invested

Capital invested by funds: $995M → $885M (-$110M)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

Holders
111
Holders Change
-5
Holders Change %
-4.31%
% of All Funds
1.87%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
15
Increased
46
Reduced
31
Closed
17
Calls
$2.57M
Puts
$5K
Net Calls
+$2.57M
Net Calls Change
+$2.57M

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$22.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$15.9M
3
BI
BVF Inc
California
+$13.5M
4
FLAM
First Light Asset Management
Minnesota
+$13.1M
5
EC
EcoR1 Capital
California
+$10.8M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$9.75M
2
VVM
Versant Venture Management
California
-$9.01M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.99M
4
ACM
Altium Capital Management
New York
-$4.48M
5
GTC
Ghost Tree Capital
New York
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
MB
26
MPM BioImpact
Massachusetts
$6.84M – – –
Charles Schwab
27
Charles Schwab
California
$6.19M +$669K +33,546 +11%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$6.18M +$284K +14,208 +4%
PAMP
29
Polar Asset Management Partners
Ontario, Canada
$3.83M +$4.09M +205,100 New
Walleye Capital
30
Walleye Capital
New York
$2.87M -$588K -29,451 -16%
First Manhattan
31
First Manhattan
New York
$2.84M – – –
NLVP
32
New Leaf Venture Partners
New York
$2.63M – – –
Morgan Stanley
33
Morgan Stanley
New York
$2.6M +$885K +44,326 +47%
SCM
34
Silverarc Capital Management
Massachusetts
$2.6M +$510K +25,535 +22%
Two Sigma Advisers
35
Two Sigma Advisers
New York
$2.42M -$230K -11,500 -8%
Victory Capital Management
36
Victory Capital Management
Texas
$2.06M – – –
Goldman Sachs
37
Goldman Sachs
New York
$1.82M -$262K -13,150 -12%
MIM
38
Monashee Investment Management
Massachusetts
$1.77M +$1.9M +95,000 New
Swiss National Bank
39
Swiss National Bank
Switzerland
$1.64M +$186K +9,300 +12%
UOC
40
UBS O'Connor
Illinois
$1.63M +$1.75M +87,460 New
Renaissance Technologies
41
Renaissance Technologies
New York
$1.61M +$1.72M +86,400 New
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$1.58M +$472K +23,663 +39%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$1.37M +$516K +25,855 +54%
AI
44
Atom Investors
Texas
$1.09M +$141K +7,065 +14%
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$1.01M +$336K +16,824 +45%
Bank of America
46
Bank of America
North Carolina
$1.01M -$871K -43,648 -45%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$1.01M +$119K +5,961 +12%
AllianceBernstein
48
AllianceBernstein
Tennessee
$955K +$431K +21,600 +73%
Citigroup
49
Citigroup
New York
$932K +$689K +34,510 +223%
Two Sigma Investments
50
Two Sigma Investments
New York
$872K -$1.48M -74,032 -61%
1
2
3 4 5

CRNX Hedge Fund Activity: Q2 2022 in Review

111 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2022, worth a combined $885M — down 11% from $995M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CRNX and 15 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 46 added.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $22.5M. The largest seller was Deep Track Capital, cutting an estimated $9.75M.

  • 111 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2022, down from 116 in Q1 2022.
  • Funds reported $885M of Crinetics Pharmaceuticals stock for Q2 2022, down 11% quarter-over-quarter.
  • 15 funds opened new Crinetics Pharmaceuticals positions in Q2 2022 and 17 closed out, a net change of -2 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2022 was Suvretta Capital Management, an estimated $22.5M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2022 was Deep Track Capital, an estimated $9.75M sold.

Based on aggregated 13F filings for Q2 2022.